Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 7Observational 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 18Melanoma 13Neoplasms 5Head and Neck Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Lung Neoplasms 4Stomach Neoplasms 3Neoplasm Metastasis 2Kidney Neoplasms 2Gastrointestinal Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Hepatocellular 2Thyroid Neoplasms 1Skin Neoplasms 1Sexual Dysfunction, Physiological 1Sarcopenia 1Recurrent Squamous Cell Lung Carcinoma 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oropharyngeal Neoplasms 1Neoplasms, Squamous Cell 1Motor Activity 1Lung Squamous Cell Carcinoma Stage IV 1Locally Advanced Melanoma 1Locally Advanced Gastric Cancer 1Liver Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Eunuchism 1Esophageal Neoplasms 1Erectile Dysfunction 1

Interventions

Blood Specimen Collection 6Surveys and Questionnaires 5Observation 3Colonoscopy 3Biopsy 3Remote Patient Monitoring 2Nivolumab 2Interviews as Topic 2Gastroscopy 2trastuzumab deruxtecan 1s-formylglutathione hydrolase 1lutetium Lu 177 dotatate 1copper dotatate CU-64 1Videotape Recording 1Validation Studies as Topic 1Ultrasonography 1Tomography, X-Ray Computed 1Standard of Care 1Specimen Handling 1Single-Balloon Enteroscopy 1Reverse Transcriptase Polymerase Chain Reaction 1Radiotherapy 1Quality of Life 1Proctectomy 1Mass Screening 1Magnetic Resonance Spectroscopy 1Lutetium-177 1Lutetium 1Induction Chemotherapy 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Gastrointestinal Neoplasms × Nivolumab × Clear all
NCT06361563 2024-04-12

Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada

Bristol-Myers Squibb

Completed
250 enrolled
Gastrointestinal

Gastrointestinal Neoplasms

NCT06361576 2024-04-12

Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada

Bristol-Myers Squibb

Completed
700 enrolled
Gastrointestinal

Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡